TNGX Stock Analysis: Tango Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 4.797m USD | 12M Return: 454.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 166M
Qual. Beats: 0
Rev. Trend: 55.5%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 5.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Tango Therapeutics, Inc. (NASDAQ: TNGX) is a clinical-stage precision oncology company that discovers and develops targeted therapies for defined patient populations with high unmet medical need. The company is headquartered in Boston, Massachusetts, was founded in 2017, and went public on the NASDAQ in September 2020. Its lead pipeline includes TNG462, a PRMT5 inhibitor in Phase 1/2 trials for pancreatic and lung cancer, and TNG456, a brain-penetrant PRMT5 inhibitor targeting glioblastoma. It is also advancing TNG260, a candidate designed to reverse immune evasion caused by STK11 loss-of-function mutations in lung cancer.
As a biotechnology company in the healthcare sector, Tango operates within the precision oncology field, which develops therapies tailored to the genetic and molecular profiles of tumors rather than treating cancer by tissue of origin alone. Like most clinical-stage biotechs at its stage, Tango relies on R&D investment and capital markets to fund development, as its drug candidates have not yet generated commercial revenue.
- TNG462 PRMT5 inhibitor Phase 1/2 data readout in pancreatic cancer
- TNG456 glioblastoma trial advances amid brain-penetrant profile
- Cash runway extension through pipeline milestones limits dilution risk
| Net Income: -107.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.17 > 0.02 and ΔFCF/TA 19.33 > 1.0 |
| NWC/Revenue: 663.2% < 20% (prev 461.1%; Δ 202.1% < -1%) |
| CFO/TA -0.32 > 3% & CFO -141.5m > Net Income -107.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 27.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (143.6m) vs 12m ago 30.17% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 16.05% > 50% (prev 14.94%; Δ 1.11% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.87 (Total Current Assets 392.3m - Total Current Liabilities 14.3m) / Total Assets 435.8m |
| B: -1.49 (Retained Earnings -648.7m / Total Assets 435.8m) |
| C: -0.30 (EBIT TTM -107.3m / Avg Total Assets 355.0m) |
| D: 8.84 (Book Value of Equity 391.5m / Total Liabilities 44.3m) |
| Altman-Z'' = 8.09 = AAA |
As of July 08, 2026, the stock is trading at USD 30.12 with a total of 2,795,003 shares traded. Over the past week, the price has changed by -7.49%, over one month by -2.62%, over three months by +52.12% and over the past year by +454.70%.
Current recommended Stop Loss: 25.90 (which is 14% or 1.9 ATR below the current price).
Tango Therapeutics has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy TNGX.
- StrongBuy: 6
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 43.8 | 45.5% |
P/S = 84.1613
P/B = 12.2515
Revenue TTM = 57.0m USD
EBIT TTM = -107.3m USD
EBITDA TTM = -105.1m USD
Long Term Debt = 30.0m USD (estimated: total debt 32.8m - short term 2.83m)
Short Term Debt = 2.83m USD (from shortTermDebt, last quarter)
Debt = 32.8m USD (from shortLongTermDebtTotal, last quarter) (leases 32.8m already included)
Net Debt = -347.1m USD (calculated: Debt 32.8m - CCE 379.8m)
Enterprise Value = 4.45b USD (4.80b + Debt 32.8m - CCE 379.8m)
Interest Coverage Ratio = unknown (Ebit TTM -107.3m / Interest Expense TTM 0.0)
EV/FCF = -58.44x (Enterprise Value 4.45b / FCF TTM -76.1m)
FCF Yield = -1.71% (FCF TTM -76.1m / Enterprise Value 4.45b)
FCF Margin = -133.6% (FCF TTM -76.1m / Revenue TTM 57.0m)
Net Margin = -188.2% (Net Income TTM -107.2m / Revenue TTM 57.0m)
Gross Margin = unknown ((Revenue TTM 57.0m - Cost of Revenue TTM 2.12m) / Revenue TTM)
Tobins Q-Ratio = 10.21 (Enterprise Value 4.45b / Total Assets 435.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 32.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -84.7m (EBIT -107.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 23.41 (Total Current Assets 392.3m / Total Current Liabilities 16.8m)
Debt / Equity = 0.08 (Debt 32.8m / totalStockholderEquity, last quarter 391.5m)
Debt / EBITDA = 3.30 (negative EBITDA) (Net Debt -347.1m / EBITDA -105.1m)
Debt / FCF = 4.56 (negative FCF - burning cash) (Net Debt -347.1m / FCF TTM -76.1m)
Total Stockholder Equity = 258.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -30.20% (Net Income -107.2m / Total Assets 435.8m)
RoE = -41.54% (Net Income TTM -107.2m / Total Stockholder Equity 258.2m)
RoCE = -37.23% (EBIT -107.3m / Capital Employed (Equity 258.2m + L.T.Debt 30.0m))
RoIC = -20.11% (negative operating profit) (NOPAT -84.7m / Invested Capital 421.4m)
WACC = 8.04% (E(4.80b)/V(4.83b) * Re(8.09%) + D(32.8m)/V(4.83b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 8.09% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 19.70%
[DCF] Fair Price = unknown (Cash Flow -76.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.38 | # QB: 0
Revenue Correlation: 55.45 | Revenue CAGR: 18.74% | SUE: -0.09 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.32 | Chg30d=+0.86% | Revisions=+29% | Analysts=11
EPS next Quarter (2026-09-30): EPS=-0.33 | Chg30d=+2.93% | Revisions=+38% | Analysts=11
EPS current Year (2026-12-31): EPS=-1.31 | Chg30d=+2.23% | Revisions=+29% | GrowthEPS=-50.5% | GrowthRev=-100.0%
EPS next Year (2027-12-31): EPS=-1.58 | Chg30d=+0.63% | Revisions=+0% | GrowthEPS=-20.7% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +35% (up=12, down=5)